Back

Platinum Priority

Reply from Authors re: Emmanuel S. Antonarakis, Howard I. Scher. Do Patients With AR-V7–Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.08.038: Unsplicing a Conflict

By: Julie Steinestela , Christof Bernemanna, Andres J. Schradera and Jochen K. Lennerzb

European Urology, Volume 71 Issue 1, January 2017, Pages 6-7

Published online: 01 January 2017

Abstract Full Text Full Text PDF (479 KB)

Refers to article:

Do Patients With AR-V7–Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions

Emmanuel S. Antonarakis and Howard I. Scher

January 2017 (Vol. 71, Issue 1, pages 4 - 6)

Refers to article:

Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer

Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, Konrad Steinestel, Martin Boegemann, Andres J. Schrader and Julie Steinestel

Accepted 14 July 2016

January 2017 (Vol. 71, Issue 1, pages 1 - 3)

Footnotes

a Clinic of Urology, University Hospital Münster, Münster, Germany

b Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA

Corresponding author. Clinic of Urology, University Hospital Münster, Albert-Schweitzer-Campus 1, Münster 48149, Germany. Tel. +49 251 8347442; Fax: +49 251 8349739.

Place a comment

Your comment *

max length: 5000